-Conference Call
Why Is Cancers/Metabolic Diseases-Focused Biomea Fusion Stock Trading Lower Today?
Biomea Fusion Inc (NASDAQ: BMEA) announced the poster presentation of long-term 26 weeks follow-up data from the first two cohorts of adults with type 2 diabetes (T2D) enrolled in the ongoing Phase 2 study (COVALENT-111) and data from preclinical ex-vivo